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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with
limited treatment options. Mutation of β-catenin is one of the most frequent genetic events along
hepatocarcinogenesis. β-catenin mutations can be in the form of point mutation or large N-terminal deletion.
Studies suggested that different β-catenin mutations might have distinct oncogenic potential.
Methods: We tested the oncogenic activity of β-cateninS45Y, one of the most frequent point mutations of
β-catenin, and ΔN90-β-catenin, a form of β-catenin with a large N-terminal deletion, in promoting HCC
development in mice. Thus, we co-expressed β-cateninS45Y or ΔN90-β-catenin together with c-Met into the
mouse liver using hydrodynamic injection.
Results: We found that both β-catenin mutations were able to induce HCC formation in combination with
c-Met at the same latency and efficiency. Tumors showed similar histological features and proliferation
rates. However, immunohistochemistry showed predominantly nuclear staining of β-catenin in c-Met/ΔN90-
β-catenin HCC, but membrane immunoreactivity in c-Met/β-cateninS45Y HCC. qRT-PCR analysis
demonstrated that both ΔN90-β-catenin and β-cateninS45Y induced the same effectors, although at
somewhat different levels. In cultured cells, both ΔN90-β-catenin and β-cateninS45Y were capable of
inducing TCF/LEF reporter expression, promoting proliferation, and inhibiting apoptosis.
Conclusions: Our study suggests that β-cateninS45Y and ΔN90-β-catenin, in combination with the c-Met
proto-oncogene, have similar oncogenic potential. Furthermore, nuclear staining of β-catenin does not
always characterize β-catenin activity.
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Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers in the world, with up to 1 million cases diag-
nosed and almost 800,000 deaths globally each year [1].
Chronic infections by hepatitis B (HBV) and C (HCV) vi-
ruses, high alcohol consumption, obesity, type II diabetes,
and exposure to aflatoxin B1 are the main risk factors for
HCC. Treatment options for HCC are still very limited. For
early stage HCC patients, surgical resection and liver trans-
plantation are potentially curative. However, due to the lack
of specific symptoms, most HCCs are diagnosed at late/
unresectable stage. For these patients, the multi-kinase in-
hibitors Sorafenib and Regorafenib provide very limited
survival benefits [2, 3]. Thus, there are major unmet med-
ical needs for the treatment of HCC and elucidating the
molecular mechanisms underlying HCC is of high
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importance to discover novel therapeutic approaches
against this deadly disease.
Recent genomic studies provide a comprehensive genetic
landscape of human HCCs. The most frequent genetic al-
terations found in this tumor type include mutations of tel-
omerase reverse transcriptase (TERT) promoter region,
TP53, ARID1A, ARID2, and CTNNB1 genes. Among them,
mutations of CTNNB1, which encodes β-catenin, were
found in 13–43% of HCCs [4–6], suggesting that the Wnt/
β-catenin cascade is a major driving oncogenic event along
HCC development.
The Wnt/β-catenin signaling pathway regulates cell pro-
liferation and differentiation, thus playing a critical role
both in development and tumorigenesis [7]. In unstimu-
lated cells, β-catenin predominantly locates at the plasma
membrane as part of the adhesion junctions (AJs). The core
of AJs consists of multiple cadherin family members, in-
cluding E-Cadherin and α-catenin in addition to β-catenin
[8]. The AJs have major roles in the stabilization of cell-cell
adhesion and regulation of actin cytoskeleton. The cyto-
plasmic pool of β-catenin is maintained at low concentra-
tion via phosphorylation of its specific serine and threonine
residues by a destruction complex. Activation of the Wnt
pathway via its ligands results in the disruption of the com-
plex, preventing β-catenin degradation. Subsequently,
β-catenin translocates to the nucleus, where it interacts with
T-cell factor (TCF)/lymphoid enhancer factor (LEF) tran-
scription factors, leading to the upregulation of various tar-
get genes, such as glutamine synthetase (GS), c-Myc, cyclin
D1, G-protein coupled receptor 5 (LGR5), and Axin2 [9–
11]. Therefore, β-catenin may have distinct roles depending
on its localization, namely at the cell membrane as part of
AJs, and in the nucleus to induce downstream gene expres-
sion. β-catenin nucleus translocation is considered a major
mechanism of activating the Wnt/β-catenin cascade in cells.
As mutations of β-catenin are one of the most frequent
genetic events during HCC development and progression,
they have been extensively studied. In particular, it has been
found that HCCs harboring β-catenin mutations tend to
occur more frequently in older patients, especially those
who are chronically infected by HBV. In addition, β-catenin
mutant HCCs mainly develop in the noncirrhotic liver,
often are well differentiated, and are associated with better
prognosis [12, 13]. Most β-catenin mutations in human
HCC occur in exon 3 at serine/threonine sites and their
neighboring amino acids. In addition, large exon 3 deletions
could also be found. All these mutations prevent the phos-
phorylation and subsequent degradation of β-catenin pro-
tein, leading to the ligand-independent activation of the
Wnt/β-catenin cascade. In a recent study, it was found that
β-catenin mutations may have different activities: large
in-frame exon 3 deletions and point mutations located at
the D32-S37 residues can induce strong β-catenin activity,
point mutations located at T41 can result in a moderate
activity, and point mutations located at S45 may be respon-
sible for a relative weak activity [11].
The c-Met protooncogene encodes a tyrosine kinase-type
growth factor receptor with an affinity for hepatocyte
growth factor (HGF). Activation of c-Met is frequently
found in human HCCs [14]. Recently, we demonstrated
that concomitant activation of c-Met and β-catenin muta-
tions could be identified in a subset of human HCCs [15].
Also, we showed that co-expression of human c-Met and a
point-mutant-β-catenin (β-cateninS45Y) via hydrodynamic
transfection leads to HCC formation in mice. Gene expres-
sion analysis confirmed that these mouse tumors mimic
the subset of human HCCs with c-Met activation and
β-catenin mutations [15].
In the present study, we investigated the oncogenic poten-
tial of the weak β-catenin mutation (β-cateninS45Y) and the
strong β-catenin mutation (ΔN90-β-catenin) in inducing
HCC formation in mice. Our investigation demonstrates
that both alterations can equally promote HCC develop-
ment in combination with the c-Met protooncogene.
Methods
Cell lines and culture
Two mouse HCC cell lines, HCC3–4 and HCC4–4, which
were derived from c-Myc transgenic mice [16], were cul-
tured in Dulbecco’s modified Eagle medium (DMEM) sup-
plemented with 10% FBS, penicillin (100 U/mL) and
streptomycin (100 μg/mL) in a humidified 5% CO2 incuba-
tor at 37 °C.
Constructs and reagents
The constructs used for mouse injection including
pT3-EF1α, pT3-EF1α-c-Met, pT3-EF1α-β-cateninS45Y
(with N-terminal Myc tag), pT3-EF1α-ΔN90-β-catenin
(with N-terminal Myc tag), and pCMV/sleeping beauty
transposase (pCMV/SB) have been described previously
[15, 17]. All the plasmids used for in vivo experiments were
purified using the Endotoxin free Maxi prep kit (Sigma-Al-
drich, St.Louis, MO) before being injected into the mice.
Super 8× TopFlash and Super 8× FopFlash plasmids were
obtained from Addgene (plasmid 12,456, plasmid 12,457);
and pRL-CMV Renilla luciferase plasmid was purchased
from Promega (Madison, WI).
Mice and hydrodynamic tail injection
Wild-type (WT) FVB/N mice were obtained from The
Jackson Laboratory (Bar Harbor, Maine, USA). Hydro-
dynamic injection was performed as described previously
[18]. In brief, 20 μg pT3-EF1α-β-cateninS45Y or
pT3-EF1α-ΔN90-β-catenin was mixed with 20 μg
pT3-EF1α-c-Met along with 1.6 μg pCMV/SB in 2 ml of
normal saline (0.9%NaCl). The solution was filtered
through 0.22 μm filter (EMD Millipore, Burlington, MA),
and injected into the lateral tail vein of 6 to 8-week-old
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FVB/N mice in 5 to 7 s. Mice were housed, fed, and moni-
tored in accord with protocols approved by the Committee
for Animal Research at the University of California San
Francisco (San Francisco, CA). All animals were carefully
monitored for signs of morbidity or discomfort. Close at-
tention was paid to the abdominal girth. Animals were
sacrificed 7 weeks after injection. Body and liver weights
were recorded.
Immunohistochemical staining
Mouse liver lesions were fixed in 4% paraformaldehyde
overnight at 4 °C and embedded in paraffin. Hematoxylin
& Eosin (H&E) staining on 4 μm liver sections was per-
formed to determine the time of appearance and character-
istics of neoplastic foci. For immunohistochemistry, antigen
retrieval was performed in 10 mM sodium citrate buffer
(pH 6.0) by placement in a microwave oven on high for
10 min, followed by a 20-min cool down at room
temperature. After a blocking step with the 5% goat serum
and Avidin-Biotin blocking kit (Vector Laboratories Inc.,
Burlingame, CA), the slides were incubated with the follow-
ing primary antibodies: mouse anti-β-catenin (1:200; BD
Transduction Laboratories™, San Jose, CA), mouse
anti-Glutamine Synthetase (1:500; BD Transduction La-
boratories™), β-catenin (D10A8) XP® Rabbit mAb (1:100;
Cell Signaling Technology, Danvers, MA), anti-Myc tag
(1:1000; Maine Medical Center Research Institute, Scarbor-
ough, ME), Ki-67 (1:150; Santa Cruz Biotechnology, Santa
Cruz, CA) overnight at 4 °C. Slides were then subjected to
3% hydrogen peroxide for 10 min to quench endogenous
peroxidase activity and subsequently the biotin conjugated
secondary antibody was applied at a 1:500 dilution for
30 min at room temperature. Signal was detected using the
Vectastain ABC Elite kit (Vector Laboratories Inc.) and de-
veloped using DAB (Vector Laboratories, Inc.). Sections
were counterstained with hematoxylin solution (Thermo-
Fisher Scientific, Pittsburgh, PA) and passed through the
dehydration process and covered-slipped.
Western blot analysis
Tissue were homogenized with a Polytron and cells were
washed in PBS and lysed in M-PER™ Mammalian Protein
Extraction Reagent (ThermoFisher Scientific) containing
the Halt™ Protease Inhibitor Cocktail (ThermoFisher Scien-
tific). Protein concentration was quantified using the
Pierce™ Microplate BCA Protein Assay Kit (ThermoFisher
Scientific). Membranes were blocked in in 5% non-fat milk
for 1 h and incubated with the following primary anti-
bodies: β-catenin (1:2000; BD Transduction Laboratories™),
p-β-catenin (Ser45; 1:1000; Cell Signaling Technology),
Myc-tag (1:2000; MMCRI), Glutamine Synthetase (1:5000;
BD Transduction Laboratories), c-Met (1:400, Invitrogen),
p-Met (Tyr1234/1235; 1:1000; Cell Signaling Technology),
cyclin D1 (1:10000; Abcam, Cambridge, UK), β-actin
(1:5000; Sigma-Aldrich) and GAPDH (1:10000; EMD Milli-
pore). Each primary antibody was followed by incubation
with secondary antibody (1:5000; Jackson ImmunoResearch
Laboratories Inc., West Grove, PA) for 1 h. After appropri-
ate washing, bands were revealed with the Super Signal
West Dura Kit (ThermoFisher Scientific).
Quantitative real-time reverse-transcription polymerase
chain reaction
Total RNAs were isolated from frozen mouse tissue
samples using the Quick-RNA™ MiniPrep (Zymo Re-
search, Irvine, CA). Reverse transcription was con-
ducted according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA). The mouse primers used for
PCR analysis were synthesized by Integrated DNA Tech-
nologies (Coralville, IA). The sequences of the primers were
as follows: ribosomal RNA (rRNA):5’-CGGCTACCACATCC
AAGGAA-3′ (Forward) and 5’-GCTGGAATTACCGC
GGCT-3′ (Reverse); Alpha Fetoprotein (AFP): 5’-TCTG
CTGGCACGCAAGAAG-3′ (Forward) and 5’-TCGG
CAGGTTCTGGAAACTG-3′ (Reverse); Glypican 3
(GPC3): 5’-CAGCCCGGACTCAAATGGG-3′ (Forward)
and 5’-CAGCCGTGCTGTTAGTTGGTA-3′ (Reverse); axis
inhibition protein 2 (AXIN2): 5’-GCTCCAGAAGATCA
CAAAGAGC-3′ (Forward) and 5’-AGCTTTGAGCCTTC
AGCATC-3′ (Reverse); G-protein coupled receptor 5
(LGR5): 5’-ACCGAGCCTTACAGAGCCT-3′ (Forward)
and 5’-GCCGTCGTCTTTATTCCATTGG-3′ (Reverse);
MYC proto-oncogene (c-Myc): 5’-TGTACCTCGTCCGA
TTCC-3′ (Forward) and 5’-CATCTTCTTGCTCTTCTTC
AG-3′ (Reverse); Cyclin D1 (CCND1): 5’-CGTGGCCTC
TAAGATGAAGGA-3′ (Forward) and 5’-CCTCGGGCC
GGATAGAGTAG-3′ (Reverse); Glutamine Synthetase (GS):
5’-CAGGCTGCCATACCAACTTCA-3′ (Forward) and 5’-
TCCTCAATGCACTTCAGACCAT-3′ (Reverse); T-Box3
(TBX3): 5’-CAGGCAGCCTTCAACTGCTT-3′ (Forward)
and 5’-GGACACAGATCTTTGAGGTTGGA-3′ (Reverse);
Ornithine Aminotransferase (OAT): 5’-GGAGTCCAC
ACCTCAGTCG-3′ (Forward) and 5’-CCACATCCC
ACATATAAATGCCT-3′ (Reverse); Leukocyte cell-derived
chemotaxin-2 (LECT2): 5’-CCCACAACAATCCTCATTT
CAGC-3′ (Forward) and 5’-ACACCTGGGTGATG
CCTTTG-3′ (Reverse). Quantitative real-time polymerase
chain reaction was performed with 100 ng of cDNA, using
an ABI Prism 7000 Sequence Detection System and Taq-
Man Universal PCR Master Mix (ThermoFisher Scientific).
Cycling conditions were: 10 min of denaturation at 95 °C
and 40 cycles at 95 °C for 15 s and at 52 °C for 1 min.
Quantitative values were calculated by using the PE Biosys-
tems Analysis software and expressed as N target (NT).
NT= 2-ΔCt, wherein the ΔCt value of each sample was cal-
culated by subtracting the maximum Ct value of the target
gene from the average Ct value of the rRNA gene.
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Dual-luciferase reporter assay
HCC3–4 and HCC4–4 cells were plated in triplicate in
24-well plate at 80–90% confluency. Cells were transfected
using the Lipofectamine 2000 reagents (Invitrogen). In
brief, each well was transfected with 600 ng of pT3-EF1α
(empty vector control) or pT3-EF1α-β-cateninS45Y or
pT3-EF1α-ΔN90-β-catenin, together with 200 ng of TOP-
Flash plasmid DNA or the negative control FOPFlash, as
well as 8 ng of pRL-CMV. Cells were harvested 48 h
post transfection. Luciferase activity was measured
using the Dual-Luciferase® Reporter Assay System
(Promega), according to the manufacturer’s protocol.
Experiments were repeated at least three times in
triplicate.
Assessment of proliferation and apoptosis
HCC3–4 and HCC4–4 cells were plated in triplicate in
24-well plate at 80–90% confluency. Cells were transfected
using the Lipofectamine 2000 reagents (Invitrogen). Prolifera-
tion and apoptosis were assessed using the BrdU Cell Prolifer-
ation Reagent (Cell Signaling Technology) and the Cell Death
Detection Elisa Plus Kit (Roche Molecular Biochemicals, In-
dianapolis, IN), respectively, following the manufacturers’
protocol. Experiments were repeated at least three times in
triplicate.
Statistical analysis
Statistical analysis was performed using Student’s
t-test and Tukey-Kramer test. The data were expressed
Fig. 1 β-catenin mutants cooperate with c-Met to promoter HCC development in mice. a Study design. b and c Liver weight and liver/body
weight ratio among wild-type mice, c-Met/β-cateninS45Y mice, and c-Met/ΔN90-β-catenin mice. Data are presented as mean ± standard
deviation. Student’s t-test: **: P < 0.01, ***: P < 0.001; NS: Not significant
Table 1 Detailed mouse data from c-Met/β-cateninS45Y and c-Met/ΔN90-β-catenin injected mice
Mice Harvest time point (weeks post injection) Liver phenotype Body weight (g) Liver weight (g) Liver/body ratio (%)
c-Met/β-cateninS45Y 7 Big tumor 25.5 5.0 19.6078
c-Met/β-cateninS45Y 7 Big tumor 29.5 14.2 48.1356
c-Met/β-cateninS45Y 7 Big tumor 25.3 10.4 41.1067
c-Met/β-cateninS45Y 7 Big tumor 22.5 7.5 33.3333
c-Met/β-cateninS45Y 7 Big tumor 26.0 6.1 23.4615
c-Met/ΔN90-β-catenin 7 Big tumor 26.4 10.3 39.0152
c-Met/ΔN90-β-catenin 7 Big tumor 27.1 10.4 38.3764
c-Met/ΔN90-β-catenin 7 Big tumor 24.6 8.3 33.7398
c-Met/ΔN90-β-catenin 7 Big tumor 27.5 12.0 43.6364
c-Met/ΔN90-β-catenin 7 Big tumor 25.8 5.9 22.8682
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as the mean ± SD of at least three independent experi-
ments. P < 0.05 was considered significant.
Results
β-cateninS45Y and ΔN90-β-catenin cooperate with c-Met
to induce HCC formation in mice
First, we investigated the oncogenic potential of “weak”
β-catenin mutant (S45Y) and “strong” β-catenin mutant
(ΔN90-β-catenin) proto-oncogenes. However, since overex-
pression of β-cateninS45Y or ΔN90-β-catenin alone does
not lead to tumor formation [15, 17, 19], we hydrodynami-
cally injected β-cateninS45Y or ΔN90-β-catenin (both with
a Myc tag) together with c-Met, a proto-oncogene fre-
quently overexpressed in human HCC, whose single over-
expression does not suffice for HCC development in mice
[14], in the mouse liver. The mice receiving the combin-
ation of plasmids were referred to as c-Met/β-cateninS45Y
and c-Met/ΔN90-β-catenin, respectively. All c-Met/β-cate-
ninS45Y or c-Met/ΔN90-β-catenin mice were harvested
after 7 weeks post injection (Fig. 1a). Upon dissection, all
c-Met/β-cateninS45 and c-Met/ΔN90-β-catenin injected
mice developed liver tumors (Table 1). Using total liver
weight as well as liver/body weight ratio as the measure-
ment of tumor burden, all c-Met/β-cateninS45Y or c-Met/
ΔN90-β-catenin injected mice had significantly increased
tumor burden when compared to wild-type mice (Fig. 1b
and c), whereas the overall tumor burden was similar be-
tween c-Met/β-cateninS45Y and c-Met/ΔN90-β-catenin
mouse cohorts (Fig. 1b and c).
Grossly, numerous tumor nodules could be found
throughout the liver parenchyma of c-Met/β-cateninS45Y
and c-Met/ΔN90-β-catenin mice (Fig. 2a). Histologically,
H&E staining of representative liver sections from c-Met/
β-cateninS45Y and c-Met/ΔN90-β-catenin mice showed
the presence of well-differentiated HCC with solid or
macro-trabecular growth pattern (Fig. 2b). Tumor cells
were highly proliferative as revealed via immunohisto-
chemical (IHC) staining of Ki-67, whereas Ki-67 positive
Fig. 2 Histological features of normal liver as well as HCCs from c-Met/β-cateninS45Y and c-Met/ΔN90-β-catenin injected mice. qRT-PCR analysis
of HCC tumor markers (a) Gross images. b H&E staining; scale bar = 200 μm. c Ki-67 IHC images; scale bar = 100 μm. d Quantification of
percentage of Ki-67 (+) cells in normal liver and mouse HCC lesions. e qRT-PCR analysis of HCC tumor markers AFP and GPC3 in normal liver and
mouse HCC lesions. Student’s t-test: *: P < 0.05; ***: P < 0.001; NS: Not significant
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cells were rarely found in normal liver (Fig. 2c). Quantifi-
cation of Ki-67 IHC demonstrated that c-Met/β-cate-
ninS45Y and c-Met/ΔN90-β-catenin HCC had similar cell
proliferation rates (Fig. 2d). Finally, qRT-PCR analysis of
HCC tumor markers AFP and GPC3 showed that both
HCC samples had higher expression of these genes than
normal liver, and there was no difference between the two
mouse HCC cohorts (Fig. 2e).
Collectively, our results suggest that β-cateninS45Y
and ΔN90-β-catenin cooperate with c-Met to promote
HCC formation in vivo at similar latency and efficiency.
Different β-catenin staining patterns between c-Met/
ΔN90-β-catenin and c-Met/β-cateninS45Y mouse HCC
Next, we performed IHC of β-catenin in normal liver as
well as HCCs from c-Met/β-cateninS45Y and c-Met/
ΔN90-β-catenin mice. Using a widely used mouse monoclo-
nal antibody against β-catenin, we found that, in normal
liver, β-catenin staining could only be detected at the hep-
atocyte membrane (Fig. 3a and b). In c-Met/ΔN90-β-cate-
nin HCC lesions, instead, strong nuclear and cytoplasm
staining of β-catenin could be readily appreciated. Surpris-
ingly, c-Met/β-cateninS45Y HCCs showed predominantly
intense membranous and very weak cytoplasmic β-catenin
staining (Fig. 3a and b). To rule out that this event may be
due to the antibody applied, we stained another set of slides
using a rabbit monoclonal antibody against β-catenin. Of
note, the same results were obtained using the second
anti-β-catenin antibody (Fig. 3c). Furthermore, as the ectop-
ically injected β-catenin construct has a N-terminal Myc
tag, we stained tumor tissue specimens with an antibody
against Myc tag. Again, we found strong nuclear/cytoplas-
mic staining pattern of β-catenin in c-Met/ΔN90-β-catenin
HCC lesions, while intense membranous immunoreactivity
of β-catenin characterized c-Met/β-cateninS45Y HCC le-
sions (Fig. 3d). As expected, no staining for Myc tag was de-
tected in the un-injected normal mouse liver tissue,
supporting the specificity of the anti-tag antibody (Fig. 3d).
At the molecular level, using Western blotting, we found
that both c-Met/β-cateninS45Y and c-Met/ΔN90-β-catenin
HCC lesions showed expression of ectopically injected hu-
man c-Met (Fig. 4), and c-Met was activated as demon-
strated by the high phosphorylated(p)-Met levels.
Ectopically expressed β-catenin could be detected via
Western blotting using an anti-β-catenin antibody as well
as a Myc tag antibody (Fig. 4). Phosphorylated β-catenin
at Ser45 could only be found in normal liver tissues; and
p-β-catenin at S33/S37/T41 was lost in c-Met/ΔN90-β-ca-
tenin HCCs (Fig. 4). Phosphorylation of β-catenin at its
C-terminal Ser552 and Ser675 residues was detected in
the endogenous and exogenous β-catenin proteins (Fig. 4).
Next, we investigated whether c-Met/β-cateninS45Y
and c-Met/ΔN90-β-catenin mouse HCCs showed similar
expression patterns of Wnt/β-catenin canonical target
genes. A total of 8 genes were analyzed via qRT-PCR, in-
cluding the pan-β-catenin targets Axin2, LGR5, c-Myc,
Fig. 3 Immunohistochemical patterns of β-catenin in normal liver and in HCC lesions of c-Met/β-cateninS45Y c-Met/ΔN90-β-catenin mice. a and
b Immunohistochemistry (IHC) of β-catenin using a mouse monoclonal antibody; scale bar = 400 μm in A; and 100 μm in B; (c) IHC of β-catenin
using a rabbit monoclonal antibody; scale bar = 100 μm; (d) IHC of ectopically injected β-catenin using an anti-Myc tag antibody;
scale bar = 100 μm
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and Cyclin D1 (Fig. 5a), as well as liver specific
β-catenin targets GS, TBX3, OAT and LECT2 (Fig. 5b).
We found that overall HCC lesions from c-Met/β-cate-
ninS45Y and c-Met/ΔN90-β-catenin mice exhibited
higher expression of β-catenin target genes than normal
liver, and the two HCC sample cohorts had similar ex-
pression patterns (Fig. 5a and b). However, some subtle
differences were noted. Specifically, by qRT-PCR, we
found that the pan-β-catenin target LGR5 expression was
higher in HCCs from c-Met/β-cateninS45Y mice than that
in c-Met/ΔN90-β-catenin mice. On the other hand, liver
specific β-catenin targets GS and OAT were expressed at
highest levels in c-Met/ΔN90-β-catenin HCC mouse le-
sions. Western blotting confirmed the higher expression
of GS in c-Met/ΔN90-β-catenin tumors and similar ex-
pression of Cyclin D1 in c-Met/β-cateninS45Y and c-Met/
ΔN90-β-catenin mouse HCCs (Fig. 4).
In summary, our study shows that β-catenin dis-
plays distinct staining patterns in c-Met/β-cate-
ninS45Y and c-Met/ΔN90-β-catenin mouse HCCs.
However, the staining patterns were not associated
with β-catenin activity, as both c-Met/β-cateninS45Y
and c-Met/ΔN90-β-catenin mouse HCCs demon-
strated high and similar expression of β-catenin tar-
get genes.
ΔN90-β-catenin and β-cateninS45Y induce TCF/LEF
reporter expression in mouse HCC cell lines
Subsequently, we evaluated the transcriptional activity of
β-cateninS45Y versus ΔN90-β-catenin with the widely used
TCF/LEF reporter constructs. Specifically, two mouse HCC
cell lines isolated from c-Myc transgenic mice, HCC3–4
and HCC4–4 cells [16], were used. These cells have high
expression of human c-Myc and no basal activation
of the Wnt/β-catenin signaling. TopFlash and FopFlash
reporter assays were carried out in these two cell lines.
Western blotting proved the successful expression of trans-
fected β-cateninS45Y and ΔN90-β-catenin plasmids
(Fig. 6a). The ratio of TOP/FOP was significantly increased
following the transfection of pT3-EF1α-β-cateninS45Y and
pT3-EF1α-ΔN90-β-catenin compared with control pT3-
EF1α empty vector (Fig. 6b). In addition, β-cateninS45Y
mutant showed significantly higher TCF/LEF reporter ac-
tivity than ΔN90-β-catenin mutant.
Fig. 4 Biochemical analysis of HCC lesions of c-Met/β-cateninS45Y c-Met/ΔN90-β-catenin mice. Western blot analysis of c-Met, p-Met, β-catenin,
Myc tag, p-β-catenin (S45), p-β-catenin (S33/S37/T41), p-β-catenin (S675), p-β-catenin (S552), GS, and cyclin D1 in normal liver as well as HCC
lesions from c-Met/β-cateninS45Y c-Met/ΔN90-β-catenin mice. GAPDH were used as a loading control. Please note the presence of two bands for
the β-catenin protein. The upper band represents endogenous β-catenin protein or β-cateninS45Y protein. The lower band represents ectopically
injected ΔN90-β-catenin protein
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Fig. 5 qRT-PCR analysis of β-catenin target gene expression in c-Met/ΔN90-β-catenin and c-Met/β-cateninS45Y mouse HCC samples. a qRT-PCR
analysis of mRNA levels of pan-β-catenin target genes: AXIN2, LGR5, c-Myc and cyclin D1. b qRT-PCR analysis of mRNA levels of liver specific β-
catenin target genes: GS, TBX3, OAT, and LECT2. Student’s t-test: *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 6 β-cateninS45Y and ΔN90-β-catenin mutants activate TCF/LEF reporter in mouse HCC cell lines. a Western blot analysis confirmed the
expression of transfected β-cateninS45Y or ΔN90-β-catenin plasmids in HCC3–4 and HCC4–4 mouse HCC cell lines. b TCF/LEF reporter activity in
HCC3–4 and HCC4–4 mouse HCC cell lines following the transfection of pT3-EF1α-β-cateninS45Y and pT3-EF1α-ΔN90-β-catenin, as analyzed using
TopFlash/FopFlash reporter assays. Student’s t-test: ***P < 0.001
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Finally, we assessed the consequence of the transfection
of β-cateninS45Y and ΔN90-β-catenin constructs in terms
of proliferation and apoptosis in HCC3–4 and HCC4–4
cells. Noticeably, both mutant forms of β-catenin were able
to induce higher proliferation and lower apoptosis than un-
treated and empty vector transfected cells (Fig. 7). Once
again, no significant differences were detected for prolifera-
tion and apoptosis between β-cateninS45Y- and ΔN90-
β-catenin-transfected cells (Fig. 7).
Discussion
Somatic mutations of β-catenin are one of the most fre-
quent genetic alterations along hepatocarcinogenesis. Spe-
cifically, in the most recently released TCGA dataset based
on whole-exome sequencing of 363 HCC cases, β-catenin
mutation was identified in 27% cases [4]. Survey of COS-
MIC database reveals that in 5306 published HCC cases,
β-catenin mutations were detected in 18.22% or 967 cases
[20]. Overall, these results demonstrate the β-catenin muta-
tion is the third most frequent somatic alteration in HCC.
Importantly, in a recent study, Torrecilla et al. analyzed the
clonal evolution of human HCCs by characterizing the mu-
tation spectrum of early stage and late stage HCC lesions
[21]. β-catenin mutation was identified as one of the three
trunk driver genetic mutations, together with TERT pro-
moter mutation and TP53 mutation, in HCCs [21]. Trunk
mutations refer to those genetic alterations that occur early
during tumor evolution, function as early drivers for
tumorigenesis [22] and are present in every tumor subclone.
These trunk mutations may therefore constitute the most
robust and reliable therapeutic targets for cancer treatment
[22]. Thus, it is critical to understand the oncogenic poten-
tial of trunk mutations, in this case β-catenin mutations, in
order to search for therapies that may lead to synthetic le-
thality in combination with β-catenin mutations for HCC
treatment.
In this study, we compared the oncogenic potential of β-
cateninS45Y and ΔN90-β-catenin mutations in combination
with c-Met proto-oncogene in promoting HCC development
using mouse modeling. In a previous study, β-cateninS45Y
was characterized as a “weak” mutant, whereas ΔN90-β-cate-
nin was characterized as a “strong” mutant [11]. We found
that at least when overexpressed in the mouse liver,
β-cateninS45Y and ΔN90-β-catenin, together with c-Met, are
capable of inducing HCC development at the same rate and
latency. Histological and molecular analysis revealed that
HCCs induced by two mutant forms of β-catenin are highly
similar. Some subtle difference in terms of gene expression
patterns was noted. GS expression has been used clinically
as the measurement of activated β-catenin in human
HCCs. In the present investigation, expression of GS was
induced at higher levels in ΔN90-β-catenin/c-Met HCC
than β-cateninS45Y/c-Met mouse HCC. Of note, in hu-
man hepatic adenoma and HCC samples, GS staining was
found to be ubiquitously strong in tumor samples with
large deletion of β-catenin, whereas human hepatic aden-
oma and HCC samples harboring β-cateninS45Y mutation
showed a diffusely heterogeneous GS staining pattern [11].
Fig. 7 β-cateninS45Y and ΔN90-β-catenin mutants similarly affect proliferation and apoptosis in mouse HCC cell lines. Relative proliferation and
apoptosis rates in HCC3–4 and HCC4–4 cell lines after transfection of the two β-catenin mutant forms at different time points (24 and 48 h). a
proliferation; (b) apoptosis. Data are presented as mean ± SD. a. vs control (untransfected cells); b. vs pT3-EF1α; c. vs pT3-EF1α-β-cateninS45Y
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At mRNA level, GS expression tends to be higher in hu-
man HCCs with “strong” β-catenin mutations than
β-cateninS45Y mutant [11]. Taken together, the results sup-
port the hypothesis that different β-catenin mutations may
induce different levels of GS expression in mouse and hu-
man HCCs.
Perhaps the most intriguing results from our current study
is that ΔN90-β-catenin/c-Met mouse HCC demonstrated
strong nuclear β-catenin staining while β-cateninS45Y/
c-Met showed predominantly membranous β-catenin
immunolabeling (Fig. 3). It is worth to note that β-catenin
may only require transient nuclear translocation to induce
downstream gene expression. One such example is that in
the normal liver, a layer of pericentral hepatocytes exhibits
activated β-catenin dependent expression of GS, but only
membrane localization of β-catenin is observed [23]. In hu-
man HCCs, tumors with β-catenin mutations show either
nuclear or membranous staining patterns. Therefore, nu-
clear β-catenin is not a reliable indicator of β-catenin muta-
tion status in both mouse and human HCC samples. Other,
markers, such as IHC of GS or qRT-PCR of Wnt/β-catenin
target genes should be used instead to measure Wnt/β-ca-
tenin activity in HCC.
Previous studies showed that approximately 10% of hu-
man HCCs have concomitant β-catenin mutations along
with c-Met overexpression [15]. β-cateninS45Y/c-Met
mouse HCC model has been shown to share similar gene
expression patterns with this subset of human HCCs [15].
Thus, the murine models with β-catenin mutations and
c-Met overexpression are excellent preclinical systems to
characterize novel targeted therapy against HCC. Our inves-
tigation suggests that β-cateninS45Y/c-Met and ΔN90-β-ca-
tenin/c-Met are equivalent in inducing HCC formation in
mice. Therefore, both models could be effectively used as a
preclinical tool to study the efficacy of new therapeutic ap-
proaches against this deadly disease.
Conclusions
Our study suggests that β-cateninS45Y and ΔN90-β-cate-
nin have similar oncogenic potential. Furthermore, nu-
clear staining of β-catenin does not always characterize
β-catenin activity.
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